# Highlights of This Issue

## SPECIAL FEATURES

### CCR Translations

- **3719**  
  Mind the Gap: Potential for Rebounds during Antiangiogenic Treatment Breaks  
  John M.L. Ebos and Roberto Pili  
  *See article p. 3961*

### CCR Perspectives in Drug Approval

- **3722**  
  Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary  

### HUMAN CANCER BIOLOGY

- **3762**  
  Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact  
  Mário Henrique M. Barros, Rocio Hassan, and Gerald Niedobitek

- **3772**  
  Defective Epidermal Innate Immunity and Resultant Superficial Dermatophytosis in Adult T-cell Leukemia/Lymphoma  
  Yu Sawada, Motonobu Nakamura, Rieko Kabashima-Kubo, Takatoshi Shimauchi, Miwa Kohayashi, and Yoshiki Tokura

- **3780**  
  FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma  
  Lisa E.S. Crose, Katherine T. Etheridge, Candy Chen, Brian Belyea, Lindsay J. Talbot, Rex C. Bentley, and Corinne M. Linardic

### Statistics in Clinical Cancer Research

- **3731**  
  Cure Models as a Useful Statistical Tool for Analyzing Survival  
  Megan Othus, Bart Barlogie, Michael L. LeBlanc, and John J. Crowley

### CCR Drug Updates

- **3737**  
  Crizotinib for ALK-Rearranged Non–Small Cell Lung Cancer: A New Targeted Therapy for a New Target  
  Leena Gandhi and Pasi A. Jänne

---

**Molecular Pathways**

- **3743**  
  Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer—Opportunities, Challenges, and Limitations  
  Jeyanthi Eswaran, Da-Qiang Li, Anil Shah, and Rakesh Kumar

- **3750**  
  Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience  
  Victor Moreno Garcia, Bristi Basu, L. Rhoda Molife, and Stan B. Kaye

---

**Review**

- **3762**  
  Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact  
  Mário Henrique M. Barros, Rocio Hassan, and Gerald Niedobitek

- **3772**  
  Defective Epidermal Innate Immunity and Resultant Superficial Dermatophytosis in Adult T-cell Leukemia/Lymphoma  
  Yu Sawada, Motonobu Nakamura, Rieko Kabashima-Kubo, Takatoshi Shimauchi, Miwa Kohayashi, and Yoshiki Tokura

- **3780**  
  FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma  
  Lisa E.S. Crose, Katherine T. Etheridge, Candy Chen, Brian Belyea, Lindsay J. Talbot, Rex C. Bentley, and Corinne M. Linardic

- **3731**  
  Cure Models as a Useful Statistical Tool for Analyzing Survival  
  Megan Othus, Bart Barlogie, Michael L. LeBlanc, and John J. Crowley

- **3737**  
  Crizotinib for ALK-Rearranged Non–Small Cell Lung Cancer: A New Targeted Therapy for a New Target  
  Leena Gandhi and Pasi A. Jänne
Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas
Luigi Scotto, Marianna Kruthof-de Julio, Luca Paoluzzi, Matko Kalac, Enrica Marchi, Jairo Baquero Buitrago, Jennifer Amengual, Michael M. Shen, and Owen A. O’Connor

Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia
Laura A. Vitale, Li-Zhen He, Lawrence J. Thomas, Jennifer Widger, Jeffrey Weidlick, Andrea Crocker, Thomas O’Neill, James Storey, Martin J. Glennie, Deanna M. Grote, Stephen M. Ansell, Henry Marsh, and Tibor Keler

Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor–Targeted Therapy
Clare McCourt, Pamela Maxwell, Roberta Mazzucchelli, Rodolfo Montironi, Marina Scarpelli, Manuel Salto-Tellez, Joe M. O’Sullivan, Daniel B. Longley, and David J.J. Waugh

Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response
Harvey Wong, Edna F. Choo, Bruno Alcicke, Xiao Ding, Hank La, Erin McNamara, Frank-Peter Theil, Jay Tibbatts, Lori S. Friedman, Cornelis E.C.A. Hop, and Stephen E. Gould

Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206
Eric Sanchez, Mingjie Li, Cathy Wang, Cydney M. Nichols, Jennifer Li, Haiming Chen, and James R. Berenson

Brachyury, a Driver of the Epithelial–Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer
Mario Roselli, Romaine I. Fernando, Fiorella Guadagni, Antonella Spilia, Jessica Alessandroni, Raffaele Palmirotta, Leopoldo Costarelli, Mary Litzinger, Duane Hamilton, Bruce Huang, Joanne Tucker, Kwong Yok Tsang, Jeffrey Schlam, and Claudia Palena

Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression
Shi Feng, Longjiang Shao, Wendong Yu, Paul Gavine, and Michael Iltmann

Resistance to TRAIL Is Mediated by DARPP-32 in Gastric Cancer
Abbes Belkhiri, Shoumin Zhu, Zheng Chen, Mohammed Sotto, and Wael El-Rifai

GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo
Jeffrey J. Wallin, Jane Guan, Wei Wei Prior, Leslie B. Lee, Leanne Berry, Lisa D. Belmont, Hartmut Koeppen, Marcia Belvin, Lori S. Friedman, and Deepak Sampath

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice
Kinya Inoue, Takuji Torimura, Toru Nakamura, Hideki Iwamoto, Hiroshi Masuda, Mitsuhiko Abe, Osamu Hashimoto, Hiromori Koga, Takato Ueno, Hirohisa Yano, and Michio Sata
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3934</td>
<td>Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma</td>
<td>Jordan Madic, Sophie Piperno-Neumann, Vincent Servois, Aurore Ramanou, Maud Milder, Bénédicte Trouiller, David Gentien, Stéphanie Saada, Franck Assayag, Aurélie Thureau, Fariba Nennati, Didier Decaudin, François-Clément Biedard, Laurence Desjardins, Pascale Mariani, Olivier Lantz, and Marc-Henri Stern</td>
</tr>
<tr>
<td>3942</td>
<td>A Replication Study and Genome-Wide Scan of Single-Nucleotide Polymorphisms Associated with Pancreatic Cancer Risk and Overall Survival</td>
<td>Jason A. Willis, Sara H. Olson, Irene Orlow, Semanti Mukherjee, Robert R. McWilliams, Robert C. Kurtz, and Robert J. Klein</td>
</tr>
<tr>
<td>3982</td>
<td>Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients</td>
<td>Moubin Lin, Jian Gu, Cathy Eng, Lee M. Ellis, Michelle A. Hildebrandt, Jie Lin, Maosheng Huang, George A. Calin, Dingzhi Wang, Raymond N. Dulkois, Ernest T. Hawk, and Xifeng Wu</td>
</tr>
<tr>
<td>3992</td>
<td>Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients</td>
<td>Moubin Lin, Jian Gu, Cathy Eng, Lee M. Ellis, Michelle A. Hildebrandt, Jie Lin, Maosheng Huang, George A. Calin, Dingzhi Wang, Raymond N. Dulkois, Ernest T. Hawk, and Xifeng Wu</td>
</tr>
<tr>
<td>3998</td>
<td>Correction: A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck</td>
<td>Y.-Y. Shao, C.-C. Huang, S.-D. Lin, C.-H. Hsu, and A.-L. Cheng</td>
</tr>
</tbody>
</table>
ABOUT THE COVER

The inhibition of androgen signaling is a major therapeutic strategy in prostate cancer; however, response is often transient, and patients ultimately relapse on therapy giving rise to a currently incurable condition known as castrate-resistant prostate cancer (CRPC). McCourt and colleagues show elevated expression of the androgen-regulated antiapoptotic protein c-FLIP in prostate cancer, which is further elevated in CRPC. Repression of c-FLIP induced apoptosis in non–castrate-resistant and CRPC cells and potentiated sensitivity to AR-targeted therapy, indicating that prostate cancer cells require c-FLIP to maintain viability. Consequently, targeting c-FLIP may represent a novel strategy to improve therapeutic response to the novel antiandrogen strategies under clinical development in CRPC. For details, see the article by McCourt and colleagues on page 3822 of this issue.